FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

WALTHAM - ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the US Food and Drug Administration has filed the...

Related Keywords

United States ,China ,American ,Michael Vasconcelles ,Anabel Chan ,Courtney Okonek ,European Medicines Agency ,Company Quarterly Reports On Form ,American Society Of Clinical Oncology ,Nasdaq ,Immunogen Inc ,National Medical Products Administration Of China ,Drug Administration ,Company Annual Report On Form ,Exchange Commission ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,Executive Vice President ,Clinical Oncology ,Marketing Authorization Application ,Medicines Agency ,New Drug Application ,Medical Products Administration ,Annual Report ,Quarterly Reports ,News Publishing ,Markets ,